JOIN US AT THE LAUNCH ROADSHOW TO LEARN ABOUT A NEW ONCE WEEKLY TREATMENT FOR MANAGING TYPE 2 DIABETES
†Please visit www.pbs.gov.au for full authority information.1
The dinner meeting will comprise expert presentations and discussions on where guidelines recommend the use of GLP-1 RAs in the treatment algorithm for type 2 diabetes and the early use of Ozempic®. Speakers will share their clinical experience with Ozempic®, practical approaches to optimising patient care and the quality use of this medicine.
*GLP-1 RA = glucagon-like peptide 1 receptor agonist.
REGISTER FOR THE OZEMPIC® LAUNCH ROADSHOW
FACE TO FACE MEETINGS
Select your location below
TOWNSVILLE
Wednesday 16 September
SYDNEY CBD
Wednesday 16 September
SYDNEY WEST
Thursday 17 September
VIRTUAL MEETINGS
The Novo Nordisk Meeting Secretariat will work with venues and suppliers to ensure they have current COVID-19 safety procedures in place as per the state and federal recommendations, additional information is available here.
A number of measures have been put in place as part for government guidelines and restrictions as well as in line for COVID safety practices. Hand sanitiser and face masks will be available for attendees whilst a maximum of four attendees per table will be allowed.
Adelaide, Perth and Townsville
| Time | Topic |
| 6:15 PM | Arrival And Registration |
| 6:30 PM | GLP-1 RA after metformin: A paradigm shift in T2DM management? |
| 7:00 PM | Introducing Ozempic®; Clinical Use and practical considerations |
| 7:30 PM | Case Study: When Metformin is no longer enough – a practical case |
| 8:00 PM | Q&A |
| 8:30 PM | Meeting Close |
Brisbane, Sydney CBD and Sydney West
| Time | Topic |
| 6:45 PM | Arrival And Registration |
| 7:00 PM | GLP-1 RA after metformin: A paradigm shift in T2DM management? |
| 7:30 PM | Introducing Ozempic®; Clinical Use and practical considerations |
| 8:00 PM | Case Study: When Metformin is no longer enough – a practical case |
| 8:30 PM | Q&A |
| 9:00 PM | Meeting Close |
Ozempic® (semaglutide), a new once-weekly GLP-1 RA* for the management of type 2 diabetes.1
*GLP-1 RA = glucagon-like peptide 1 receptor agonist.
PBS Information: Authority Required (STREAMLINED). Type 2 diabetes.
Criteria Apply. Refer to PBS Schedule for full Authority Required Information.
For enquiries on your registration or more information about the roadshow please contact us at:
Novo Nordisk Meeting Secretariat
Privacy Policy | Terms of Service | Contact Us
Ozempic® is a registered trademark of Novo Nordisk A/S. Novo Nordisk Pharmaceuticals Pty. Ltd.
Level 3, 21 Solent Circuit, Baulkham Hills NSW 2153. ABN 40 002 879 996. NovaCare® Customer Care Centre (Australia) 1800 668 626. https://www.novonordisk.com.au. Date of preparation: August 2020. AU20OZM00152.
.